Aida Pharmaceuticals (AIDA)

[QFA2008]

How many shares for this acquisition ? If Aida uses cash for the acquisition, why Aida need sell uints for plant to product Rh-Apo2L ?
Total cost of this acquisition is about RMB 71,180,000 and they said “in a share transfer agreement”.

Jiangsu Institute of Microbiology Co., Ltd is the patent inventor of Aida current product – Etimicin.
Aida has long history relationship with the institute. I visited Jiangsu Institute of Microbiology Chinese website (http://www.aflatoxin.cn/). It has a lot of products. But I cannot find any thing about ‘Wetimicin, a new generation Aminoglycoside antibiotic, which is now in Phase I clinical trial stage” in today’s PR.
This purchase make Aida has strong Pharmaceutical R&D position in China. Now Aida has three Pharmaceutical Cos (Hangzhou Aida, Aike and Changzhou Fangyuan) and three R&D institutes(Qiaer, Boda and today’s JSIM).
Based upon Aida current position, 30m market cap is very very cheap I think.